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LIST OF ABBREVIATIONS 
 
ARFI – Acoustic Radiation Force Impulse  
ROI – Region of Interest  
RTE – Real-Time Elastography  
SWE– Shear-Wave Elastography  
SR – Strain Ratio  
SRI – Strain Rate Imaging  
SSI – Supersonic Shear Imaging  
TE –Transient Elastography  
US – Ultrasonography  
VCS – Visual Categorical Score  
OVs - Oesophageal varices  
LS - liver stiffness  
NAFL - non-alcoholic fatty liver  
NASH – non-alcoholic steatohepatitis  
NAS - NAFLD activity score  
pSWE - Point shear-wave elastography  
2-D SWE – 2-dimensional shear-wave elastography 
HVPG - pressure gradient of the hepatic vein  
Kilo Pascal - kPa 
Metres per second - m/s 
AUROCs - (Area under the Received Curves) 
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ABSTRACT 
Background: The cirrhotic process of liver injury is the end-stage of hepatic fibrosis, which results 
from progressive accumulation of extracellular matrix during the wound-healing response of the 
liver to repeated injury.  
Mortality and morbidity rates increase exponentially once cirrhosis develops. Therefore, a prompt 
assessment of the degree of severity of fibrosis, an accurate and timely diagnosis of liver cirrhosis 
and management of complications are important in guiding therapy management in chronic liver 
disease. Liver biopsy is often required, but it is an invasive procedure, with a risk of severe 
complications (1/4000–10,000). In addition, its accuracy is prone to sampling error (6) and inter-
and/or intra-observer diagnostic discrepancies occur in up to 10–20% of liver biopsies. For this 
reason, there is increasing interest in non-invasive methods for detecting liver fibrosis.  
Ultrasound-based transient elastography (TE) is one of the first non-invasive imaging methods to be 
used in common practice. The technique is based on low-frequency vibrations: shear waves 
produced by the ultrasound machine propagate through the tissue and produce an elastic 
deformation, with the premise that liver stiffness (LS) measurements reflect the degree of hepatic 
fibrosis. Displacement is reflected in the variation of the acquired echo signals. The Siemens-based 
ARFI system and Philips Elast PQTM use conventional US to generate a shear wave directly within 
the liver tissues. This allows the sonographer to obtain both conventional US images and also 
specify a region of interest (ROI) for estimation of liver stiffness. The propagation velocity of the 
shear wave is reported in metres per second, and correlates with liver stiffness. The direct 
generation of shear wave within the liver tissue holds advantages over TE since it is not subject to 
chest/abdominal wall distortion of the waves.  
Results: 110 consecutive patients with liver disease underwent a liver biopsy and liver stiffness 
assessment by Philips EPIQ 7TM ultrasound system, Siemens Acuson (ARFI) ultrasound system, 
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and      Echosens FibroscanTM (currently the best-validated technique). The results of these three 
imaging techniques were compared with histological results.  
A direct, strong correlation was observed between LS values assessed by TE elastography by Elast 
PQ and Virtual Touch (p < 0.0001) and Metavir score. 
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LIVER DAMAGE 
Hepatic fibrosis can be defined as a dynamic process involving cellular, molecular and tissue 
processes which leads to the accumulation of components of the cellular matrix (ECM) in the liver 
parenchyma [8]. The pathologies associated with the development of liver fibrosis include chronic 
infection by hepatotropic viruses (HBV and HCV), chronic exposure to toxic substances (the most 
common cause being alcohol misure), chronic exposure to altered metabolic conditions and damage 
caused by autoimmune alterations. The chronic liver damage caused by a chronic inflammatory 
response, combined with other pathogenetic mechanisms, such as oxidative stress, alteration of the 
relationship between mesenchymal and epithelial cells and the activation of fibrogenesis, leads to 
an unbalanced process which favours the formation of fibrous tissue [9-13]. The accumulation of 
extracellular matrix proteins determines a progressive alteration of the liver architecture, initially 
characterised by the formation of fibrous septa, as a result of regenerative nodules, with the 
subsequent development of cirrhosis. Cirrhosis causes hepatocellular dysfunction and determines an 
increase in resistance of hepatic blood circulation with the development of hepatic insufficiency and 
portal hypertension [14]. In most patients, the progression to cirrhosis occurs over a period of 15-20 
years. 
The main complications of cirrhosis include ascites, renal failure, hepatic encephalopathy and 
variceal bleeding. Patients with compensated cirrhosis do not develop complications for many 
years, whereas decompensated cirrhosis is associated with reduced survival; the only effective 
therapeutic strategy is liver transplant. Cirrhosis is also a risk factor for the development of 
hepatocellular carcinoma [15].  
In recent years, substantial progress has been made in understanding the mechanisms that regulate 
fibrogenesis. In hepatic fibrosis hepatic stellate cells (HSCs), also called Ito cells or perisinusoidal 
cells, play a fundamental role, as an essential element for the production of collagen in the liver. 
This type of cell, described for the first time by Kupffer in 1876, undergoes a radical phenotypic 
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change in the presence of chronic liver disease, with consequent acquisition of fibrogenic properties 
[15]. In addition to hepatic stellate cells, portal myofibroblasts and bone marrow cells also appear to 
have fibrogenic potential [16]. 
The natural history of liver fibrosis is influenced by both genetic and environmental factors. The 
genes that regulate apoptosis and/or hepatocellular necrosis (Bcl-xL, Fas) affect the extension of 
liver damage and the subsequent fibrogenic response [17]. Genes regulating inflammatory response 
to liver injury (IL-1, IL 6, IL 10, IL-13, IFN, SOCS- 1 and osteopontin) determine the fibrogenic 
response to injury itself [17], while the genes that mediate the production of ROS (NADPH 
oxidase) regulate both inflammatory response and the deposition of extracellular matrix [18]. 
Fibrogenic growth factors (TGF-1, FGF), vasoactive substances (angiotensin II, norepinephrine) 
and adipokines (leptin and adiponectin) are necessary elements for the development of fibrosis [19]. 
Excess collagen removal is regulated by TIMP-1 and TGF-1 [20]. 
When the liver suffers an acute damaging stimulus, the parenchymal cells regenerate themselves 
and replace the necrotic or apoptotic cells. This process determines an inflammatory response and a 
limited deposition of extracellular matrix. If the damaging stimulus persists, the liver cells are no 
longer able to regenerate and the hepatocytes are replaced by abundant extracellular matrix, 
composed primarily of collagen fibres. The arrangement of the fibrous tissue depends on the type of 
damaging stimulus. In chronic viral liver disease and cholestatic hepatitis, fibrous tissue is localised 
initially in the portal spaces; in alcoholic liver disease it is localised in perisinusoidal areas [21]. 
Liver fibrosis is characterised by alterations in both the quantity and composition of the 
extracellular matrix. In advanced stages of fibrosis, the liver contains a quantity of extracellular 
matrix approximately six times higher than normal, predominantly consisting of collagen (I, III and 
IV), fibronectin, elastin, laminin, hyaluronic acid and proteoglycans. This extracellular matrix 
accumulation is caused by an increase in its synthesis and reduction in its degradation. The reduced 
activity of the metallo-proteinase (MMP), the enzymes responsible for extracellular matrix 
degradation, essentially depends on the increase in their specific inhibitors (TIMPs) [22]. 
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Hepatic stellate cells (HSCs) are the main cells responsible for producing extracellular matrix in 
liver damage. In the normal liver, HSCs are localised in the space of Disse and store vitamin A. 
During liver injury, HSCs are activated and differentiate into fibrogenic and proliferating 
myofibroblasts [23]. Activated HSCs migrate and accumulate in the area of damaged tissue, 
producing a large amount of extracellular matrix and regulating its degradation. The Platelet-
Derived Growth Factor (PDGF), produced primarily by Kupffer cells, is the most important 
mitogenic agent for HSCs. Collagen synthesis in HSCs is regulated both at the transcriptional level 
and the post-transcriptional [24]. The increase in collagen messenger RNA stability results in a 
greater production of this protein by activated HSCs [25]. 
In addition to hepatic stellate cells, other cell lines have fibrogenic potential. The myofibroblasts 
from small portal vessels proliferate around biliary tracts initiating collagen deposition in the liver 
fibrosis caused by cholestatic [26] disease. In addition, experiments on in vitro culture of 
hematopoietic stem cells CD34 + CD38- with different growth factor cells have led to the 
differentiation of hepatic stellate cells (HSCs) and myofibroblasts derived from bone marrow, able 
to localise in human liver tissue, resulting in remodelling of tissue architecture [27]. 
Moreover, the damaged hepatocytes produce reactive oxygen species (ROS) and fibrogenic 
mediators with consequent recruitment of inflammatory cells. Apoptosis of damaged hepatocytes 
stimulates collagen production by liver myofibroblasts [28]. The inflammatory cells, both 
polymorphonuclear and lymphocytic, activate the hepatic stellate cells with consequent production 
of collagen [29]. The activated hepatic stellate cells secrete inflammatory chemokines, express cell 
adhesion molecules and modulate the activation of lymphocytes [30]. In addition, the fibrogenic 
process is influenced by different subtypes of T helper lymphocytes present and the Th2 response is 
associated with an increased fibrogenesis [31]. Kupffer cells are resident macrophages that play an 
important role in liver inflammation by releasing ROS and cytokines [32]. Changes in extracellular 
matrix composition are able to directly stimulate fibrogenesis. Type IV collagen, fibrinogen and 
Sebastiana Maria Atzori. Elastografia epatica: metodiche a confronto, 
Scuola di dottorato in Scienze Biomediche, Università degli studi di Sassari. 
10 
urokinase-type plasminogen activator stimulate hepatic stellate cells through the activation of latent 
cytokines, such as TGF-1 [33]. 
The monocyte chemotactic protein-1 stimulates fibrogenesis, while IL-10 and IFN have the 
opposite effect [34]. Among the growth factors, TGF is a key mediator in human fibrogenesis, 
stimulating synthesis of extracellular matrix proteins and inhibiting their degradation [35]. The 
platelet-derived growth factor (PDGF) is the most important mitogen for hepatic stellate cells and 
its production increases in the fibrotic liver [36]. Cytokines with vasoactive properties regulate liver 
fibrogenesis. Substances that promote vasodilation (nitric oxide, relaxin) have antifibrotic effects, 
while substances that promote vasoconstriction (norepinephrine, angiotensin II) have the opposite 
effects [37]. Among the vasoactive cytokines, angiotensin II seems to play an important role in liver 
fibrogenesis; it is involved in liver inflammation and stimulates the proliferation and migration of 
hepatic stellate cells, the production of proinflammatory cytokines and collagen synthesis [39-40]. 
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HISTOLOGICAL ASSESSMENT OF LIVER FIBROSIS 
Histological assessment of the liver is able to quantify liver damage by identifying the necro-
inflammatory grade or "grading" and the degree of fibrosis or "staging". 
Grading 
Grading is a histological evaluation of the necro-inflammatory state of the liver, and is identified by 
the following characteristics:   
1. Quantity of inflammatory infiltrate (consisting of rare lymphocytes and plasma cells) in the portal 
tracts, hepatic artery and portal vein branches and biliary interlobular ducts within the fibrous 
matrix. 
2. Quantity of periportal and lobular necrosis and destruction of hepatocytes induced by 
inflammatory cells (piecemeal necrosis). 
3. Entities of confluent necrosis exceeding the limiting lamina and combining or forming bridges 
between vascular structures or, even more important, portals (bridging necrosis). 
4. Quantity of degeneration of hepatocytes and focal necrosis within the lobule. All these data 
provide the histological grading of the disease [41, 42]. 
Staging  
Staging is a histological evaluation of liver fibrosis and reflects the level of disease progression. 
Semi-quantitative estimation of histological damage   
In order to classify these histological alterations, the following standardised semi-quantitative 
scoring systems have been developed and are used in clinical practice. 
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Knodell  
In 1981 Knodell and colleagues proposed a scoring system based on a numerical index of 
histological activity (Histology Activity Index, HAI). The model considers four separate scores for 
each component of the lesion: from 0 to 10 for periportal necrosis with or without bridging necrosis, 
0 to 4 for intralobular degeneration and focal necrosis, 0 to 4 for portal inflammation, and 0 to 4 for 
fibrosis. The first three categories assess the intensity of inflammatory activity (grading) while the 
fourth indicates the degree of fibrosis (staging). In this model fibrosis scores are used on a 
discontinuous scale. Fibrosis is classified thus:  
0 = absent  
1 = fibrous portal expansion  
3 = bridging fibrosis (porto-portal and porto-central)  
4 = cirrhosis. 
The main limitation of this system is that it groups necro-inflammatory activity and fibrosis, while 
these parameters describe different types of lesion and have different prognostic implications [43].  
HISTOLOGICAL 
PATTERN 
SEVERITY  SCORE  
 
Periportal necrosis 
piecemeal necrosis (PN) 




PN Moderate  
PN Severe  
PN + BN Moderate  
PN + BN Severe  
Lobular necrosis                  10    
 
 0  
 1  
 3  
 4  
 5  











    0  
    1  
    3  
    4  
 







    0  
    1  
    3  
    4  
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In1994 Ishak and colleagues proposed a revision of the Knodell model with some changes. This 
system uses a continuous scale of values that describes the degree of activity and the stage of 
fibrosis as two separate parameters [44]. Grading assessment is carried out separately, considering 
the different forms of necrosis and attributing a maximum score of 18 for the necro-inflammatory 











    0  
    1  
    3  
    4  
Maximum score                               22  
HISTOLOGICAL 
PATTERN  
SEVERITY SCORE  
 
Piecemeal necrosis  
 
Absent 
Mild few mild focal areas) 
Mild/Moderate  




     0 
     1  
     2 
     3 
     4  
 




Zone 3 necrosis in some areas 
Zone 3 necrosis in most areas 
Zone 3 necrosis + occasional 
portal-central bridging  





     0  
     1  
     2  
     3  
     4  
 
     5  
 
     6  
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This system is less complex than the HAI and it can assess the portal/periportal component and the 
necro-inflammatory component separately. 
Metavir  
This classification system was proposed by the French cooperative study group METAVIR, and 
provided two separate scores for the evaluation of histological activity and fibrosis stage. It reflects 
the combination of lobular necrosis, portal inflammation, piecemeal necrosis and bridging necrosis. 
The activity ranges from 0 to 3. Fibrosis is classified into four stages [45]. 
HISTOLOGICAL PATTERN  SCORE  
No fibrosis        0  
Enlargement of portal tract without septa 
formation  
      1  
Rare septa formation (> 1 septum)        2  
Several septa        3  
Cirrhosis       4  
Non-alcoholic fatty liver (NAFL) 
Steatosis is a result of excess accumulation of triglycerides in the liver. The threshold for 
considering steatosis as an abnormal feature is 5% hepatocytes. Steatosis is usually macrovesicular, 
but may be either purely large droplet or a mixture of small and large droplets (mediovesicular 
 
Focal lytic necrosis, apoptosis 
and focal inflammation 
 
Absent 
One focus or less per 10 x 
objective 
2 to 4 foci 
5 to 10 foci  
More than 10 foci 
 
 
     0  
 
     1  
     2 
     3 
     4 
Portal inflammation  Absent  
Mild, some or all portal areas 
Moderate, some or all portal 
areas  
Moderate/Marked, all portal 
areas   
Marked, all portal areas  
 
     0  
     1 
 
     2 
 
     3 
     4  
                                                      Maximum score                               18 
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steatosis). In macrovesicular steatosis, the lipid vacuole almost entirely fills the hepatocyte, pushing 
the nucleus to the side. Mediovesicular steatosis occurs when there are one or more smaller 
vacuoles in the cytoplasm. Microvesicular steatosis is a rare form in which the hepatocyte 
cytoplasm is replaced by innumerable small vacuoles, giving the cell a foamy appearance. True 
diffuse microvesicular steatosis is uncommon, but it may occur with patchy distribution in up to 
10% of NAFLD. Steatosis may be distributed in a distinctly zone 3 (pericentral) centred pattern, but 
abundant steatosis can be panacinar, and when resolving, it may be irregular throughout the whole 
acinus. It is rare for steatosis to be localised in zone 1 (characteristic pattern of paediatric NAFLD), 
and as the disease progresses towards cirrhosis, steatosis may become more irregularly distributed 
or may vanish. A simple four-scale grading system (from 0 to 3) is used for grading steatosis. It 
takes into account only macro- and/or mediovesicular steatosis and assesses the percentage of 
hepatocytes decorated by steatotic vacuoles [19]. Normal liver (Grade 0) contains fat in < 5% of 
hepatocytes, while grade 1 steatosis refers to 33% steatotic hepatocytes. In grade 2 and 3 steatosis, 
fat is present in at least 33% or 66% of hepatocytes, respectively [46].  
The relationship between steatosis and steatohepatitis is unclear. Although the natural history of 
NAFLD is still incompletely understood, it is clear that those who have the histological pattern of 
non-alcoholic steatohepatitis (NASH) and advanced fibrosis are at much greater risk of developing 
end-stage liver disease, liver-related mortality or extra-hepatic mortality than the general population 
of the same age and sex [47-48].  
There are no non-invasive tests that can be performed to firmly identify patients with steatohepatitis 
or distinguish steatohepatitis from pure steatosis. Therefore, if there is a need to know with certainty 
whether or not a patient has NASH, a liver biopsy must be performed [49]. It is uniformly accepted 
that two cardinal features - lobular inflammation and liver cell clarification/ballooning - are 
mandatory features for NASH diagnosis. These patterns have been characterised best in the adult 
liver in which the lesions centre around the terminal hepatic vein, but once fibrosis progresses and 
parenchymal remodelling occurs, the lesions may lose preferential acinar localisation [50].  
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Inflammation is more often lobular in NASH, typically more prominent than portal inflammation in 
uncomplicated adult NAFLD. It consists mainly of clusters of mononuclear, but also Kupffer cells, 
microgranulomas with or without the lipid droplets, sometimes associated with hepatocyte dropout 
or apoptotic bodies. Neutrophil aggregates are rare and become prominent only if numerous 
Mallory–Denk bodies are present. The degree of lobular inflammation is usually mild and, when 
abundant, should suggest another or associated aetiology such as alcohol or drug toxicity [51].  
Ballooned hepatocytes need to display both clear, flocculent, non-vacuolar cytoplasm, with a 
ballooned shape, as defined by the loss of the sharp angles of the liver cell. Size may or may not be 
increased compared to the size of normal hepatocytes. In the NAFLD activity score (NAS), 
ballooned cell grading is based mainly on number (none, few, many), while in the SAF score, it is 
mainly based on the size of ballooned cells.  
Other features of hepatocellular injury may also be observed, such as apoptotic bodies, but they are 
usually sparse and inconstant. Mallory–Denk bodies may be present but they are less well-formed 
than in alcoholic hepatitis or alcoholic steatohepatitis and sometimes detected only by using p62 or 
ubiquitin immunohistochemistry. They can be numerous in severe NASH, but numerous Mallory–
Denk bodies may suggest an associated alcoholic or toxic injury. The presence of Mallory–Denk 
bodies correlates with the histological severity of steatohepatitis and with other markers of 
progression and fibrosis in NASH [52].  
NAFLD displays a continuous spectrum of steatosis, hepatocyte damage and inflammatory and 
fibrous lesions. Therefore, the categorisation of NAFLD into two subgroups (NASH, no NASH) is 
an oversimplification. Semi-quantitative scoring systems may partially avoid this limit. 
NAFLD activity score (NAS) 
NAS is based on the concept that necroinflammatory lesions and fibrosis stage should be separately 
evaluated, as the former is potentially more reversible than the latter. NAS was created as an 
unweighted score for steatosis (0–3), lobular inflammation (0–3) and ballooning (0–2). 
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Steatosis 0 < 3% 
 1 5-33% 
 2 33-66% 
 3 >66% 
Lobular inflammation 0 No foci 
 1 < 2 foci/200x 
 2 2-4 foci/200x 
 3 > 4 foci/200 x 
Hepatocyte ballooning 0 None 
 1 Few balloon cells  
 2 Many cells/prominent ballooning 
SAF (Steatosis, Activity, Fibrosis) score 
Steatosis NAS Activity Fibrosis 
0-3 0-8 0-4 
0 <  5 % Steatosis 0-3 0 Normal 
1 5-33 %  + Balloonisation 0-2 1 Central 
2 34-66%  + Inflammation 0-3 2 Central + portal 
3 67-100%  3 Septal fibrosis 
  4 Cirrhosis 
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LIVER BIOPSY  
Liver biopsy has long been the “gold standard” for the diagnosis, staging and follow-up of liver 
diseases and is currently the comparison method in comparative studies on the efficiency of non-
invasive diagnostic markers of fibrosis. The biopsy for liver disease can be performed by the 
percutaneous, laparoscopic or transjugular approach. 
INDICATIONS FOR LIVER BIOPSY [53] 
• Multiple parenchymal liver disease  
• Abnormal liver function tests of unknown origin  
• Fever of unknown origin  
• Focal or diffuse abnormalities in imaging studies  
• Prognostic-staging of known parenchymal liver disease  
• Management-developing treatment plans based on histologic results. 
ABSOLUTE CONTRAINDICATIONS [53] 
• Uncooperative patient 
• Platelets <50,000/mm  
• Severe coagulopathy  
• Infectious diathesis of the liver parenchyma  
RELATIVE [53] 
Ascites 
Possible vascular lesions  
Amyloidosis 
Hydatid disease 
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The percutaneous biopsy is the most rapid, secure and most widely used approach for studying, 
grading and staging diffuse liver disease. In addition, most of the centres now use echo-assisted or 
ultrasound-guided percutaneous biopsy with a significantly reduced number of complications 
[54,55,56,57]. 
After the liver biopsy, the patient must remain under observation for 6 hours. During that period 
clinical parameters including blood pressure and heart rate should be monitored. Liver biopsy is a 
procedure that can be performed in an outpatient setting. Liver biopsy complications rarely occur. 
60% of complications occur within 2 hours and 96% within 24 hours of the procedure. A proportion 
of patients between 1% and 3% require hospitalisation for complications [58]. 
Minor complications include transient post-biopsy pain in the right hypochondrium area, 
experienced by patients in approximately 30% of cases, and the resulting transient hypotension with 
a vaso-vagal reaction. Major complications include intraperitoneal bleeding, subcapsular or 
intraparenchymal haematoma, haemobilia and accidental puncture of other organs such as the lung, 
kidney, gall bladder or colon, resulting in bile peritonitis, pneumothorax, subcutaneous emphysema, 
pleural effusion, haemothorax, sepsis or abscesses and haemoptysis [59]. With improved techniques 
and tools and ultrasound devices, the major complications have decreased substantially over time 
and currently range between 0.3% and 12.57% [60]. 
Post-procedure mortality varies from 0.01% to 0.17% and is mostly caused by bleeding in patients 
with cirrhosis or primitive malignant lesions of the liver [61]. Another important aspect to consider 
is the cost of this diagnostic procedure [62]. The main limitations of the histological assessment of 
liver biopsy are sampling error and variability in inter- and intra-observer interpretation. Sampling 
error is closely related to irregular distribution of liver damage and involves both staging and necro-
inflammatory grading that is usually underestimated. The importance of sampling errors has 
recently been emphasised by one study on liver biopsies, obtained by the laparoscopic approach 
which showed differences in excess of one point of the fibrosis score according to Scheuer between 
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the left lobe and right lobe in about one third of cases (30.4 %); however in 14.5% of cases the 
diagnosis of cirrhosis was made in one lobe but, not the other [63].  
Autopsy studies and laparoscopic comparison indicate that liver biopsy underestimates cirrhosis in 
10-30% of cases, depending on the type of needle used and the size of the sample taken [64, 65]. 
Sampling error decreases in proportion to the increase in size of the biopsy specimen. Generally, for 
an accurate diagnosis a sample of liver 1.5-2.5 cm in length and 1.2-2 mm thick is necessary [46]. 
The importance of sample size is demonstrated by a study that showed that correct diagnosis is 
possible in 65% of cases with samples of 15 mm length and above 75% of cases with cores of 25 
mm length [46]. The number of portal tracts in the sample is also very important; the sample must 
include at least eleven portal spaces [46]. 
 
PORTAL HYPERTENSION 
Portal hypertension (PHT) is a clinical syndrome defined by a portal venous pressure gradient 
between the portal vein (PV) and inferior vena cava exceeding 5 mmHg [1]. Cirrhotic PHT is 
associated with an elevated hepatic venous pressure gradient (HVPG) predominantly due to raised 
sinusoidal resistance. non-cirrhotic PHT (NCPH), HVPG is normal or only mildly elevated and is 
significantly lower than PV pressure.  
Non-cirrhotic Portal Fibrosis (NCPF) variously called as Idiopathic PHT (IPH), hepatoportal 
sclerosis and obliterative venopathy, is a disorder of unknown etiology, clinically characterized by 
features of PHT; moderate to massive splenomegaly, with or without hypersplenism, preserved 
liver functions, and patent hepatic and portal veins. 
Rarity of the disease in the west, a declining trend with improved standards of living and hygienic 
conditions support the role of infections, of imprecise nature, at an early age in the disease 
pathogenesis. Role of prothrombotic disorders in the pathogenesis is supported by autopsy studies 
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showing high prevalence of PV thrombosis (PVT) and studies from the west indicating association 
with prothrombotic states. Immunological basis is propagated due to female preponderance, 
association with various immunological and autoimmune disorders, and presence in serum of 
various autoantibodies. phlebosclerosis, fibroelastosis, periportal, and perisinusoidal fibrosis, 
aberrant vessels in portal tract (portal angiomatosis), preserved lobular architecture, and differential 
atrophy.  Main PV trunk is dilated with thick sclerosed walls, along with thrombosis in medium and 
small PV branches – the histological hallmark termed ‘‘obliterative portal venopathy’’. Long term 
survival after eradication of esophagogastric varices and after a properly timed shunt surgery is 
nearly 100% and 80%, respectively [17,101]. Liver functions usually remain well preserved, but 
with course of time in 20–33% of cases, liver slowly undergoes parenchymal atrophy with 
subsequent decompensation, development of HPS and need for LTx [102,103]. follow-up study, 
PVT, ascites and liver failure have been shown to develop in 46%, 50%, and 21%, respectively, 
over a mean period of 7.6 years – the later 2 complications were associated with variceal bleeding, 
surgery or concurrent extrahepatic disease [14]. Worsening of preexisting PHT and development of 
new PVT occurred in 46% and 28%, respectively, with a proportion requiring LTx [15]. 
Development of PVT is thus considered a major event contributing to progression of liver disease 
and eventual decompensation. However, the same has not been shown in the transplant and autopsy 
series  
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NON-INVASIVE METHODS FOR EVALUATION OF LIVER FIBROSIS  
In recent years, research has focused on the evaluation of non-invasive methods for the assessment 
of liver fibrosis.  
According to EASL guidelines, non-invasive methods are not merely an alternative to biopsy for 
staging fibrosis, but also predictive of the incidence of liver-related complications of liver fibrosis, 
including HCC development [66]. 
Non-invasive methods rely on two different approaches: a biological approach based on the 
quantification of biomarkers in serum samples or a “physical” approach based on the measurement 
of liver stiffness (LS). 
SERUM MARKERS OF LIVER FIBROSIS  
Serum markers of liver fibrosis are divided into direct and indirect markers. Indirect markers reflect 
the liver damage and include routine laboratory parameters such as GOT/AST transaminases and 
GPT/ALT, platelet count, gamma globulin, albumin, cholinesterase and INR. Direct markers reflect 
the changes in the extracellular matrix and enzymes. This category includes part of the 
glycoproteins, such as hyaluronic acid and laminin, collagens, such as procollagen III and collagen 
type IV and matrix metalloproteinases (MMPs) and their inhibitors (TIMPs). The advantage of 
serum markers is that they are universally available and reproducible. However, they can be 
influenced by comorbidities and medications that need to be considered when the results are 




Fibrotest patented formula combining α-2-macroglobulin, 
γGT, apolipoprotein A1, haptoglobin, total bilirubin, 
age and gender 
Forns Index 7.811 - 3.131 x ln(platelet count) + 0.781 x ln(GGT) + 
3.467 x ln(age) - 0.014 x (cholesterol) 
AST to Platelet Ratio (APRI) AST (/ULN)/platelet (109/L) x 100 
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FibroSpect IITM patented formula combining α-2-macroglobulin, 
hyaluronate and TIMP-1 
MP3 0.5903 x log(PIIINP [ng/ml]) - 0.1749 x log(MMP-1 
[ng/ml]) 
Enhanced Liver Fibrosis scoreTM (ELF) patented formula combining age, hyaluronate, 
MMP-3 and TIMP-1 
Fibrosis Probability Index (FPI) 10.929 + (1.827 x Ln[AST]) + (0.081 x age) + (0.768 x 
past alcohol use*) + (0.385 x HOMA-IR) –(0.447 x 
cholesterol) 
HepascoreTM patented formula combining bilirubin, γGT, 
hyaluronate, α-2- 
macroglobulin, age and gender 
FibrometerTM patented formula combining platelet count, 
prothrombin index, AST, α-2-macroglobulin, 
hyaluronate, urea and age 
Lok index -5.56 - 0.0089 x platelet (103/mm3) + 1.26 x 
AST/ALT ratio = 5.27 x INR 
Gotebörg University Cirrhosis Index (GUCI) AST x prothrombin - INR x 100/platelet 
Virahep-C model -5.17 + 0.20 x race + 0.07 x age (yr) + 1.19 ln(AST 
[IU/L]) - 1.76 ln(platelet count [103/ml]) + 1.38 
ln(alkaline phosphatase (IU/L]) 
Fibroindex 1.738 - 0.064 x (platelets [104/mm3]) + 0.005 x (AST 
[IU/L]) + 0.463 x (gamma globulin [g/dl]) 
HALT-C model -3.66 - 0.00995 x platelets (103/ml) + 0.008 x serum 




Hui score 3.148 + 0.167 x BMI + 0.088 x bilirubin - 0.151 x 
albumin - 0.019 x platelet 
Zeng score -13.995 + 3.220 log(α-2-macroglobulin) + 3.096 




FIB-4 age (yr) x AST [U/L]/(platelets [109/L] x (ALT 
[U/L])1/2 
SHASTA index -3.84 + 1.70 (1 if HA 41-85 ng/ml, 0 otherwise) + 
3.28 (1 if HA >85 ng/ml, 0 otherwise) + 1.58 
(albumin <3.5 g/dl, 0 otherwise) + 1.78 (1 if AST >60 




NAFLD Fibrosis Score (NFS) (-1.675 + 0.037 x age (yr) + 0.094 x BMI (kg/m2) + 
1.13 x IFG/diabetes (yes = 1, no = 0) + 0.99 x 
AST/ALT ratio - 0.013 x platelet count (x109/L) - 
0.66 x albumin [g/dl]) 
BARD score (BMI ≥28  
Steato TestTM ALT, A2M, ApoA1, haptoglobin, total bilirubin, 
GGT, total cholesterol, TG, glucose, age, 
gender and BMI 
Fatty liver index 
(FLI) 
BMI, TG, WC, and GGT 
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BMI, and diabetes 
Lipid accumulation 
product (LAP) 
WC, TG and gender 
Index of NASH 
(ION)  
Male: waist-to-hip ratio, TG, ALT and HOMA 
Female: TG, ALT and HOMA 
MS, diabetes, insulin, AST/ALT  
Table 1: A2M a2-macroglobulin, ALD alcoholic liver disease, ALT alanine transaminase, AST aspartate 
transaminase, ApoA1 apolipoprotein A-1, BMI body mass index, CHB chronic hepatitis B, CHC chronic 
hepatitis C, CLD chronic liver disease, GGT gamma-glutamyl transferase, LB liver biopsy, MRS magnetic 
resonance spectroscopy, MS metabolic syndrome, SLD suspected liver disease, TG triglycerides, US 
ultrasonography, WC waist circumference [71] 
 
Several multi-parameter scores that combine direct and/or indirect serum markers were evaluated 
and some of these are commercially available. APRI (AST/platelet) and FibroTestTM have been 
studied the most. Two meta-analyses, which included 8,739 and 4,266 patients with chronic 
hepatitis C virus, reported good accuracy (> 80%) for the APRI in diagnosing significant fibrosis, 
but poor accuracy for the diagnosis of intermediate stages of fibrosis [67, 68]. APRI shows less 
diagnostic accuracy in the liver fibrosis stages caused by chronic HBV infection. The FibroTestTM 
consists of a combination of indirect markers. A meta-analysis that evaluated the diagnostic 
performance of FibroTestTM showed good diagnostic accuracy (> 80%) in diagnosing significant 
fibrosis (F METAVIR> 2) and liver cirrhosis (F = 4) in patients with chronic liver disease [69]. A 
study that included 1,307 patients with a viral infection (HCV 913, 284 HBV, HIV 110) and 
prospectively compared the FibroTestTM, Fibrometer, Hepascore and APRI, showed no significant 
difference between the various diagnostic methods in the diagnosis of significant fibrosis (AUROC 
0.72- 0.78) and liver cirrhosis (AUROC 0.77-0.86) [70]. Several algorithms using a combination of 
serological markers to optimise the staging of liver fibrosis were evaluated. In a study that included 
2,035 patients with chronic liver disease, the use of a sequential combination of APRI and 
FibroTestTM (SAFE biopsy) led to a reduction of 47% in the biopsies for diagnosing significant 
fibrosis and 82% in the diagnosis of cirrhosis of the liver [70]. Other combinations of algorithms, 
such as Fibropaca (a simultaneous combination of FibroTestTM, APRI and Forns-Index) and Leroy 
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(a simultaneous combination of APRI and FibroTestTM) showed comparable results in patients with 
HCV-related chronic liver disease.  
LIVER STIFFNESS IMAGING TECHNIQUES  
Liver elasticity-based imaging techniques are divided into ultrasound-based techniques and 3-D 
magnetic resonance (MR) elastography [71]. 
Ultrasound elastography can currently be performed by different techniques, which are based on 
two physical principles: strain displacement/imaging and shear-wave imaging and quantification. 
Both strain elastography and SWE require mechanical excitation of tissue by manual compression 
(or cardiovascular pulsation and respiration), by the use of acoustic radiation force impulse (ARFI), 
or by a controlled external vibration. Strain elastography looks at the distribution of strain 
(measurement of tissue deformation) within a specified region of interest. SWE monitors the 
propagation of shear waves in tissues. The underlying principle for several, although not all, US-
based techniques is that the velocity of a shear wave propagating through the liver is proportional to 
liver stiffness represented by the equation for Young’ s elastic modulus E (E=3rv2), where v is 
shear velocity and r is tissue density, assumed to be constant. Shear waves propagate faster in stiffer 
tissue.  
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Figure 1: Principle of elastography methods [72] 
Physical principles 
Shear waves are transverse (i.e. the particle movement is across the direction of travel, as occurs in 
the ripples of a water surface when it is disturbed); they are rapidly attenuated by tissue; they travel 
slowly (between 1 and 10 m/s) and are not supported by low viscosity liquids. Their speed is related 
to Young’s modulus of elasticity. Shear waves are produced by any mechanical disturbance and 
occur naturally from muscular movements (voluntary, cardiac etc.) as well as being induced by the 
ultrasound systems used to measure their speed. 
There are three methods of shear-wave speed measurement in shear-wave elastography: 
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 Point shear-wave elastography (pSWE): a small measurement box (usually 5x10mm) is set 
up within the tissue and readings made of the shear-wave speed. 
 2-D shear-wave elastography: there are multiple sequential pushing and measurement 
points, so that a single static SWE image may be built up and displayed as a colour-coded 
map of the shear-wave speed which is quantitative (a ROI gives the readouts). 
 Another form of elastography that is currently available also uses ARFI, but any shear wave 
generated is ignored and instead the amplitude of the displacement generated in the vicinity 
of the pushing beam’s focus is displayed and used as a surrogate for the inverse of Young’s 
modulus. Such displacement lasts only milliseconds and an image must be built slowly from 
multiple positions of the pushing focus, producing a qualitative static elastogram [73]. 
A dynamic force is mandatory for generating a shear wave. Elastography methods are divided into 
quasi-static methods and dynamic methods. When an ultrasound transducer is used to displace the 
tissue surface, this is referred to as quasi-static compression. It is caused by manual compression 
and decompression.  
In dynamic methods an acoustic radiation force impulse induced by a high-energy ultrasound beam 
creates a shear wave or elasticity measured indirectly in kPa.  
Ultrasound uses elastography images to observe the tissue deformation determined by shear waves. 
Pressure on the tissue surface causes a variation in density, and the perturbations generated travel 
together as a longitudinal wave. The longitudinal wave velocity cl (about 1540ms-1) is determined 
almost entirely by the density ρ of the tissue and the elasticity of compression modulus K. In an 
ideal situation (an elastically homogeneous medium of infinite spatial extent) the (transverse) shear-
wave propagation speed cs is determined by ρ and the shear elastic modulus G. Because in soft 
tissues G is much smaller than K, shear waves travel about 1,000 times slower than longitudinal 
waves, typically in the range 1 – 10ms1. Unlike longitudinal waves, ultrasonic shear-wave 
frequencies are attenuated rapidly in soft tissue. Hence very low frequencies, often below 1 kHz 
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(which includes static deformations), must be used for elastography. Moreover, non-viscous pure 
fluids do not propagate shear waves [73].  
All current commercial elastography systems need to measure shear-wave tissue displacement. The 
various systems differ in how the displacement is used; it may be measured directly, converted to 
strain, or used to detect the time of arrival of shear waves and hence their speed. 
Measurements of the shear modulus G and its close relative Young’s modulus E may be made non-
invasively, if one can monitor the displacements of the tissue elements as a function of time as a 
shear wave passes multiple points along its path. For example, in TE and SWE, G is obtained from 
shear-wave speed measured as the difference in shear-wave arrival time at two or more points 
separated by known distances. In addition, both the percentage deformation (known as strain) and 
the displacement generated are directly dependent on the value of G for a given force, and both 
have been employed, in different elastography techniques, to display shear modulus contrast of 
tissues [73].  
Quasi-static method 
In quasi-static strain imaging, axial and lateral tracking is applied between each pair of RF-echo 
frames and the lateral displacements are discarded leaving a sequence of axial displacement images. 
Each axial displacement image is then converted into a strain image by passing a moving window 
(the strain-estimation window) down each image line, to calculate the local axial gradient of 
displacement at each window position. The size of the strain-estimation window is chosen as a 
compromise between strain image resolution (small window) and good strain signal-to-noise ratio 
[73].  
Dynamic methods 
Dynamic methods also use the tissue displacement estimation techniques employed in SE but differ 
in the method of applying the force or in the way that displacement is used. The localised 
displacement induced by a focused acoustic radiation force impulse may be displayed directly. 
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Alternatively, propagation of a transient displacement may be used to determine shear-wave speed. 
The dynamic nature of the force is essential in both cases.  
 
Acoustic radiation force can create a localised displacement of a few microns in the ultrasound axial 
direction, which decays in a few ms [74]. Sufficient force for this purpose can be generated with a 
standard ultrasound scanner at depths of many centimetres by a sequence of rapid bursts of long 
focused ultrasound pulses [75]. The displacement is measured at a known time after cessation of the 
push using RF-echo tracking, and displayed as a qualitative elastogram within a small box [76]. 
 
Transient elastography employs a brief push (a small “thump”) applied with an automated 
movement of the ultrasound transducer, which acts like a piston at the skin surface. The shear wave 
arises from the edge of the piston. A component of the wave converges on the ultrasound axis and 
after some distance travels down the axis at a speed close to the shear-wave speed. The shear 
displacement and depth is then measured using 1D correlation tracking methods, and the speed of 
the wave obtained from a displacement M-mode as the slope of a straight line. A special algorithm 
rejects displacement M-modes that are not linear enough. The shear-wave speed can be converted to 
a Young’s modulus value using the relation E=3 ρcs 2, and the measurement given in kPa.  
The system lacks 2D image guidance of the measurement, and it is not possible to propagate the 
shear wave beyond fluid collections (ascites). It may be difficult to obtain sufficient signals in obese 
patients with the standard probe (3.5 MHz, 2mm vibration amplitude), although the failure rate has 
been reduced by the introduction of a dedicated XL probe (2.5 MHz, 3mm vibration amplitude).  
On the other hand, the use of the ribs for support when generating the intercostal transient shear 
wave limits the amount of prestress, which can be a confounding factor in elastography.  
The transient surface displacement is also tightly controlled, as a single-cycle of a 50Hz wave. This 
is expected to help reproducibility of the measurements because tissue elasticity and hence shear-
wave speed depends on the frequency of vibration. Finally, since the shear wave is not generated by 
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acoustic radiation force, it is relatively easy to keep the ultrasound thermal and mechanical indices 
low. 
SWE can be used to produce two- or three-dimensional quantitative images of shear-wave speed 
with a useful field of view (2D SWE or 3D SWE).   
The acoustic radiation force focus is swept down the acoustic axis, so as to generate tissue 
displacements. This produces a shear wave in the shape of a cone with a shallow angle (and hence 
almost cylindrical), known as a Mach cone, that travels away from the push line, which spreads less 
and thus decays less rapidly with distance than that from a single pushing focus. An ultrafast 
scanner achieves an ultrasound frame rate of up to 20 kHz by transmitting a plane wave and 
focusing only on receive, so that each ultrasound echo image is created with a single transmit pulse. 
This high frame rate allows the shear waves to be followed in real time in 2D, and RF-echo tracking 
over a grid of points produces a displacement movie and small map of shear-wave time-of-arrival 
can be created. The process is repeated for a number of different push lines to create a final 
quantitative elasticity image in a box, which is presented as a colour overlay on the B-mode image 
in units of ms-1, or converted to Young’s modulus in kPa as for TE [77, 78]. The maximum size of 
the elastogram box is approximately 2–3 cm of side length with a linear transducer, and 9 x 4 cm 
with a convex transducer. Thus the system uses three frame rates: the standard B-mode echo image, 
a hidden ultrafast echo image used to track the displacement, and the shear-wave elastogram. 
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Table 2: Types of elastography [73] 
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This is a one-dimensional ultrasonographic method that relies on the FibroscanTM (Echosens, Paris, 
France) device, which measures the velocity of an ultrasound wave at low frequency (50 Hz) 
propagating through the liver. This speed is directly related to tissue stiffness.  
TE was the first ultrasound-based elastographic technique for the liver, introduced in 2003, and has 
the largest body of evidence. 
FibroscanTM measurements are performed with the patient in the supine position; the probe is 
placed on the skin surface in a lateral position using a right intercostal approach (usually between 
the 9th and 11th intercostal spaces). The operator then presses the button located on the probe to 
perform the measurement. Liver stiffness measurement is performed in a cylinder approximately 1 
cm wide by 4 cm in length at between 25 and 65 cm beneath the surface of the skin. The software 
determines whether the measurement was successful, and if so, the machine does not show a value 
on the display. The result is considered valid if ten valid measurements are performed: if the 
success rate (success rate, ratio of valid measurements and total number of measurements) is above 
60%; if the interquartile range (IQR that reflects the variability of measurements) is less than 30% 
of the median (M) of the measurements (IQR/M <0.30%).  
The results are expressed in kiloPascals (kPa) and vary between 1.5 and 75 kPa, with normal values 
around 7 kPa, and higher values in men and patients with low or high body mass index (body mass 
index, BMI) [79,80]. The advantages of FibroscanTM are the speed of the procedure, the ability to 
have immediate results, and the possibility of testing both at the patient's bedside or in the clinic. It 
is also simple to use and can be performed by a nurse or technician after training. Nevertheless, 
FibroscanTM results must be interpreted according to the patient's clinical presentation, hepatopathy 
aetiology and laboratory parameters. Although the FibroscanTM has excellent inter- and intra-
observer concordance (with an intra-class correlation coefficient of 0.98) [81,82], its accuracy is 
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lower in patients with higher transaminase levels. In the large case reported (13,369 examinations) 
[83], it was impossible to obtain a measurement result in 3.1% of cases, and in 15.8% of cases the 
results were not reliable (did not obtain the reliability criteria recommended by the manufacturer), 
mainly due to patient obesity or limited operator experience. Similar results were obtained in 
another study of 3,206 patients with a failure rate of 2.7% in measurements and an unreliability 
percentage of 11.6% [84].  
Among the other parameters, IQR/M (Interquartile Range/Median) less than 30% has been 
suggested by the manufacturer to be the most important [85]. In one study [86] conducted on 1,165 
patients, 798 of whom suffering from HCV-related chronic liver disease in which liver biopsy was 
used as the gold standard, in the multivariate analysis reliability of the results was tied to IQR/M 
increased to 30% and to liver stiffness measurement. It was observed that liver stiffness 
measurements higher than 7 kPa and IQR/M greater than 30% were associated with lower 
reliability of the results. However, higher reliability was observed in the group of patients with 
IQR/M lower than 30% regardless of the outcome of liver fibrosis. In order to reduce the number of 
patients with unreliable results due to obesity, a new probe was developed (XL, with 2.5 MHz 
transducer), enabling liver stiffness measurements at a depth between 35 and 75 mm [87, 88 89]. 
One study [89] conducted on 275 patients with chronic liver diseases (viral hepatitis 42%, 46% 
NAFLD) and BMI greater than 28 kg/m2, showed that failure in obtaining results was less frequent 
when they used the XL probe, compared with the standard M probe (1.1% vs 16%; p <0.00005). 
The study showed that unreliable results decreased with the XL probe in 25% of cases compared to 
50% of cases with the M probe (p <0.00005) and the values obtained with the XL probe were lower 
than those obtained with the M probe. 
FibroscanTM results are also difficult to obtain in patients with narrow intercostal spaces and almost 
impossible in patients with ascites [90]. Moreover, inflammation, extrahepatic cholestasis or 
congestion can interfere with liver stiffness measurements. Confounding effects that can lead to 
overestimation have been noticed in increased transaminases, extrahepatic cholestasis, the presence 
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of congestive heart failure and food intake. For this reason, FibroscanTM  measurements should 
always be carried out with the patient having fasted for at least 2 hours [91-92-93-94]. The 
influence of steatosis on the results of FibroscanTM measurements is still under debate. Although 
some studies have shown that there is a correlation between the degree of steatosis and liver 
stiffness levels measured by FibroscanTM [95], more recent studies have denied this correlation [96, 
97]. The FibroscanTM was initially validated for the assessment of patients with HCV-related 
chronic liver disease. Subsequent investigations that have been conducted have validated this 
method for other chronic liver diseases. In HCV in chronic liver disease, levels greater than 6.8-7.6 
kPa liver stiffness are related to the presence of significant fibrosis (F2). The cut-off values that 
predict the presence of cirrhosis are between 11.8 and 13.3 kPa [98,99,100,101]. 
With regard to chronic HBV-related liver disease a study of 202 patients showed cut-off values of 
7.2 and 11 kPa, respectively, for significant fibrosis and cirrhosis [102]. The areas under the curve 
were respectively 0.81 and 0.93 for significant fibrosis and cirrhosis of the liver. A study conducted 
on 140 patients with HBV-related liver disease and 317 patients with HCV-related liver disease 
[103] showed a higher correlation in patients with chronic HCV-related liver disease: r = 0.578 vs r 
= 0.408 (p = 0.02). The average stiffness values of the liver measured by FibroscanTM are similar 
for each stage of fibrosis in patients with chronic hepatitis B and C. However, a further study [104] 
conducted on 202 patients with chronic hepatitis C and 363 with chronic hepatitis B showed the 
same accuracy, sensitivity and specificity, and predictive value in patients with chronic hepatitis B 
and C. A study in an Asian population [105] showed that FibroscanTM-measured liver stiffness 
results  were not affected by transaminase levels, while other studies showed a correlation [90]. In 
the studies conducted up to now, FibroscanTM results have not been accurate in differentiating 
between contiguous stages of fibrosis (especially in the F1 and F2 stages) but have shown greater 
sensitivity in differentiating between the absence of significant fibrosis and fibrosis and between 
significant fibrosis and cirrhosis. A meta-analysis showed a cut-off value of 7.6 kPa (AUROC 
average of 0.84) for significant fibrosis and an optimum cut-off value of 13 kPa (0.94 AUROC 
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average) for cirrhosis [98]. In a further meta-analysis, the optimum cut-off values were 7.3 kPa and 
15 kPa for significant fibrosis and cirrhosis, respectively [106]. 
In chronic alcohol-based liver disease, there is coexistence with inflammation and fibrosis can 
affect the liver stiffness results measured by FibroscanTM. Several studies have found higher cut-off 
levels, compared to those seen in patients with viral hepatitis for the diagnosis of cirrhosis (19.5 
kPa, 22.6 kPa) [107]. However, in these studies the patients enrolled had elevated transaminase 
levels. A study of patients with alcoholic hepatitis showed that liver stiffness levels measured by 
FibroscanTM decreased with the reduction in transaminases [108]. A greater decrease was observed 
in particular with the reduction in AST and no significant increase in liver stiffness was observed 
for values of AST levels <100 U/L.  
Several studies have shown that the FibroscanTM is considered an important tool in assessing the 
severity of C virus recovery in patients undergoing liver transplantation [109].  
The FibroscanTM was also tested to evaluate complications of liver cirrhosis like portal 
hypertension. For the evaluation of portal hypertension the invasive detection of the hepatic venous 
pressure gradient (HVPG) remains the gold standard. A value greater than 10 mmHg can indicate 
the presence of clinically significant portal hypertension and a value higher than 12 mmHg may 
indicate the risk of bleeding from oesophageal varices [110]. In this study, the ROC curves for 
predicting portal hypertension were 0.945 with cut-off values of between 13.6 kPa and 21 kPa. 
Furthermore, the study observed greater correlation of the FibroscanTM measurements when HVPG 
measurement was less than 12 mmHg. Another study evaluated 100 patients with chronic liver 
disease performing HVPG and FibroscanTM measurements on the same day and following them up 
for the next two years. The study results showed that FibroscanTM measurement had similar 
accuracy to HVPG measurement in assessing the presence of portal hypertension (AUROC 0.830 
vs 0.845) [111]. The cut-off proposed for estimating the presence of oesophageal varices in the 
various studies performed varied between 19.8 kPa and 47.5 kPa (AUROC 0.72-0.78) [112, 113]. A 
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further study showed different cut-off values in order to estimate the presence of oesophageal 
varices depending on the aetiology [114]. 
ACOUSTIC RADIATION FORCE IMPULSE (ARFI)   
The acoustic radiation force impulse is a phenomenon associated with the propagation of acoustic 
waves in a medium of attenuation. The ARFI system is integrated within a conventional ultrasound, 
and the region of interest (ROI) for elastography measurement can be chosen under the B-mode 
vision. The tissue is stressed using an acoustic pulse that propagates through it. The energy 
transferred to the tissue by the acoustic impulse generates a deformation of the tissue itself. Soft 
tissues are more elastic and deform more than a rigid tissue whose deformability is lower. The 
deformation associated with the propagation of an ultrasonic pulse is then followed by a relaxation 
process, after which the tissue returns to its original position. ARFI elastography is used in the 
Siemens Acuson S2000TM Ultrasound (Siemens AG, Erlangen, Germany) with a 4CI probe. The 
same principle is present in the Philips EPIQTM, Samsung, Hitachi and Esaote ultrasound systems. 
Results are expressed in metres per second (m/s). Like TE, this method gives better diagnostic 
results for liver cirrhosis and for the diagnosis of significant fibrosis. A meta-analysis that included 
518 patients [115] with chronic liver disease (83% with chronic liver disease on a viral base) 
showed an AUROC value of 0.87 for the diagnosis of significant fibrosis, 0.91 for severe fibrosis 
and 0.93 for liver cirrhosis. 
In another meta-analysis that included 36 studies (21 articles and 15 abstracts) for a total of 3,951 
patients a value of 0.84 AUROCs was obtained and 0.91 for the diagnosis of significant fibrosis, 
severe fibrosis and liver cirrhosis, respectively [116]. The cut-off values suggested by the two meta-
analyses were 1.34 to 1.35 m/s, 1.55-1.61 m/s, and 1.80-1.87 m/s for the diagnosis of significant 
fibrosis, severe fibrosis and liver cirrhosis, respectively. Studies comparing the two methods, 
FibroscanTM and ARFI, showed conflicting results. A recent meta-analysis [117] which included 13 
studies with a total of 1,163 patients (11 articles and 2 abstracts) did not observe a significant 
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difference between the diagnostic reliability of ARFI and FibroscanTM. For the diagnosis of 
significant fibrosis, sensitivity and specificity were 0.74 and 0.83 for the ARFI, and 0.78 and 0.84 
for the FibroscanTM, respectively. For liver cirrhosis diagnosis, sensitivity and specificity were 0.87 
and 0.87 for the ARFI and 0.89 and 0.87 for the FibroscanTM, respectively. Reliable measurements 
were obtained in more patients with the ARFI system rather than with the FibroscanTM (98% versus 
93%, respectively, P <0.001). 
REAL TIME SHEAR-WAVE ELASTOGRAPHY 
Real-time shear-wave elastography is performed using the AixplorerTM ultrasound system 
(SuperSonic Imagine S.A., Aix-en-Provence, France) with a convex probe (SC6-1) and it is also 
included in the GE and Toshiba ultrasound systems. In this method ultrasonic waves are created in 
the tissue by the radiant acoustic force generated by focused ultrasonic pulses. Ultrasonic waves 
then propagate through a given tissue and speed is then estimated using Doppler acquisition. The 
velocity of the sound waves can be used to calculate tissue stiffness by the formula E = pc2, where 
E is tissue elasticity (in kilopascal, kPa), p is tissue density (kg/m3) and c is the velocity of the tissue 
ultrasound waves (m/s). The speed estimate is then encoded using a colorimetric system by creating 
a quantitative image of two-dimensional shear wave tissue stiffness that is shown in a box in 
conventional B-mode images. The size and position of the shear-wave image is determined by the 
operator by positioning a circular region of interest (ROI) within the B-mode image. In addition to 
the tissue stiffness expressed in kPa, mean and standard deviation are calculated for the region of 
interest.  
The first study published on this method that was compared with TE showed good diagnostic 
accuracy (AUROC 0.94 for significant fibrosis, 0.96 for severe fibrosis and 0.96 for cirrhosis) 
[118]. Another study [119] proposed a cut-off for F≥2 7.4 kPa (AUROC 0.91), for F≥3 8.7 kPa 
(AUROC 0.99) and for F = 4 9.2 kPa (AUROC 0.97). 
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ASSOCIATION BETWEEN FIBROSCAN AND SERUM MARKERS 
Several algorithms have been proposed in which a combination of FibroscanTM  and serum markers 
must be used to evaluate liver fibrosis. An algorithm that considers FibroscanTM and FibroTestTM 
(Castera/Bordeaux algorithm) was evaluated in order to optimise non-invasive diagnosis in patients 
with chronic hepatitis C [120]. According to this algorithm, if both methods are in agreement, 
hepatic biopsy is not needed; if liver biopsy is differentiated it could be ………should be 
performed. The combination of other elastographic methods and serum markers could be equally 
useful. Using such algorithms, biopsies could be reduced by 50-70%. 
 
Figure 2: Castera/Bordeaux algorithm 
For patients with chronic Hepatitis B several algorithms were proposed [121-122]. The proposed 








FS > 7.1 kPa and FT 
< 0.48 (n 48) 
F < 7.1 kPa 
and FT > 0.48 
(n 29) 
FS failure 
(n 8) Agree 
FS > 7.1 kPa 
and FT < 0.48 
(n 87)  
FS > 7.1 kPa 






Sebastiana Maria Atzori. Elastografia epatica: metodiche a confronto, 
Scuola di dottorato in Scienze Biomediche, Università degli studi di Sassari. 
39 
 
Figure 3: Algorithm in chronic Hepatitis B  
PROGNOSTIC VALUE OF NON-INVASIVE TESTS  
Shear-wave elastography and serum markers have shown good results in several studies in detecting 
the presence or bleeding of oesophageal varices by associating elastographic measurement, spleen 
size and platelet count. Recently it has been shown that splenic stiffness measured by shear-wave 
elastography has shown a better association with hepatic venous pressure, varicose veins and 
varicose veins and bleeding [123-124]. 
Several studies have shown an increased risk of developing hepatocellular carcinoma (HCC) in 
patients with chronic viral hepatitis with high FibroscanTM values. A recent study with 1,555 
patients with chronic hepatitis B showed that FibroscanTM score improved the diagnosis of HCC. 
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Using a cut-off value of 11, FibroscanTM was able to exclude HCC development at 5 years with a 
high predictive value of 99-100% negative [125]. 
In a prospective study involving 1,457 patients with chronic hepatitis C, all patients underwent on 
the same day liver biopsy, FibroscanTM measurement and FibroTestTM, with FIB-4 and APRI serum 
markers at zero time and during a five-year follow-up. Patients with METAVIR score F3/F4 had a 
lower five-year survival rate compared to METAVIR F0/F2 patients. Similar results were obtained 
using FibroscanTM: patients with FibroscanTM values <9 and greater than 9.5 kPa had a 5 year 
survival rate of 77% and 96%, respectively. Patients with FibroTestTM values greater than 0.95 kPa 
had a five-year survival rate of 0%, while patients with FibroTestTM values below 0.75 kPa had a 
survival rate of 97%. 
Comparable results were obtained in a study that combined FibroscanTM and FibroTestTM to 
evaluate five-year survival in patients with chronic Hepatitis B [126-127].  
PORTAL HYPERTENSION 
Portal hypertension is haemodynamically defined by an increase in the venous pressure gradient 
across the liver, calculated from its inflow through the portal vein versus its outflow through the 
hepatic veins. An increase in resistance to portal blood flow is the initial factor that leads to a rise in 
portal pressure. This resistance can be located at any point in the liver circulation, i.e. at the 
prehepatic, intrahepatic or post-hepatic level. In the Western world, 90% of cases of PH are due to 
advanced chronic liver disease (ACLD) or cirrhosis, which cause structural damage through 
fibrogenesis, parenchymal extinction and regeneration. PH then develops at the intrahepatic 
sinusoidal site. Other less common causes include vascular liver diseases, such as extrahepatic 
portal vein obstruction, thrombosis of the hepatic veins (Budd-Chiari syndrome, BCS) and 
idiopathic PH. Sinusoidal PH in patients with cirrhosis can be reliably and safely evaluated by 
measuring the hepatic venous pressure gradient (HVPG) via hepatic vein catheterization. An HVPG 
of up to 5 mmHg is considered normal; subclinical PH is defined by an HVPG of 6–9 mmHg; and 
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an HVPGP10 mmHg represents the ‘clinically significant’ PH threshold.4 When HVPG reaches 10 
mmHg or above, PH can become symptomatic as patients can develop gastroesophageal varices and 
hyperdynamic circulation, increasing their risk of clinical decompensation. Upper gastrointestinal 
endoscopy is the best method to determine the presence of oesophageal and gastric varices, and 
allows the identification of additional signs used to stratify bleeding risk. 
Liver stiffness measurement (LSM) accurately reflects liver fibrosis in CLD.17 In patients with 
CLD, fibrosis is the major component of increased intrahepatic vascular resistance leading to PH 
(as discussed above). Therefore, LSM has been studied as a possible surrogate for PH. The spleen 
undergoes parenchymal remodelling in patients with PH. This is partly attributable to passive 
congestion and increased arterial inflow, and partly because of increased hyperactive splenic 
lymphoid tissue and enhanced angiogenesis and fibrogenesis, leading to the progressive 
development of splenomegaly in most patients. Ultrasound studies showed that spleen vascular 
resistance (estimated by Doppler pulsatility and resistance indexes) is increased in patients with PH, 
and correlates with PH severity and complications. Spleen stiffness measurement (SSM) by 
ultrasound elastography could be an accurate non-invasive surrogate for PH, and devoid of the 
limitations of LSM. Studies comparing LSM and SSM (measured by TE in an adequate left 
intercostal space using technical conditions similar to those used for LSM) showed that the spleen is 
substantially stiffer than the liver in both healthy subjects and patients with chronic liver disease.  
 
CONTROLLED ATTENUATION PARAMETER (CAP score)  
Since ultrasound propagation is influenced by the presence of fat in the tissue, new software has 
been developed to quantify steatosis. This parameter is based on the ultrasonic properties of the 
radiofrequency signals that are retropropagated and acquired by FibroscanTM. It is called the 
Controlled Attenuation Parameter (CAP score) and is generated by a process based on vibration-
controlled transient elastography (VCTE) [128-129]. The CAP measures the degree of ultrasound 
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attenuation by hepatic fat at the central frequency of the FibroscanTM M probe (3.5 MHz). Results 
are expressed in decibels per metre (dB/m).  
Several studies reported that the CAP correlated fairly well with biopsy proven steatosis and 
significantly differentiated between S0, S1 and S2 patients. However, a significant difference could 
not be detected in subjects with advanced disease (S2–S3) [130-131]. 
Cut-off values vary from one study to another, but the cut-off values associated with significant 
steatosis (33% of hepatocytes) was almost always 250 dB/m. [132]. 
Another study reported that larger skin capsular distance (SCD), obesity and metabolic syndrome, 
when measuring CAP, may cause overestimation of steatosis [133-134-135-136-137]. A CAP 
algorithm for the FibroscanTM XL probe, specifically designed for the obese population, is being 
developed [139]. A recent study on 324 patients with biopsy-proven NAFLD found that CAP, 
directly related to steatosis and obesity, is independently linked to increased liver stiffness (LS) 
values, especially in patients with lower stages of fibrosis. A higher rate of false-positive LS results 
for the assessment of fibrosis by TE in patients in the higher CAP tertiles was noticed. The study 
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METHODOLOGY 
AIMS & OBJECTIVES 
1. To correlate liver stiffness assessed by the Philips EPIQ 7TM ultrasound system, Siemens 
Acuson (ARFI) ultrasound system, and Echosens FibroscanTM (currently the best-validated 
technique), and compare the results of these three imaging techniques with histological results in 
patients suffering from chronic liver disease with different aetiologies.  
2. To determine cut-off values of the liver stiffness (LS) measurements that correlate with the 
histological fibrosis stage.  
3. To detect variations in liver stiffness (LS) measurements correlated with different parameters:  
diagnostic blood tests  
blood pressure  
anthropometric parameters: body mass index (BMI) 
4. To correlate CAP score with the histological results of liver biopsy. 
STUDY DESIGN  
This is an imaging study to compare the results of three imaging techniques (Philips Shear Wave 
Ultrasound, Siemens Acuson ARFI and Echosens FibroscanTM) with the clinical diagnostic results 
of liver biopsies.  
100 patients were studied using the Philips Ultrasound System, Siemens ARFI Acuson and 
FibroscanTM immediately prior to the liver biopsy.  
INCLUSION CRITERIA:  
 Able and willing to provide written informed consent;  
 Aged between 18 and 75;  
 Chronic liver disease;  
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 About to undergo a liver biopsy as part of standard routine clinical care, or if a liver biopsy 
has already recently been performed, is willing to attend for a specific research visit for the 
three scans;  
 Willing to consent to medical notes and diagnostic test results being reviewed, captured, and 
recorded by the clinical research study team.  
EXCLUSION CRITERIA:  
 Unable or unwilling to give written informed consent;  
 Aged under 18 or over 75;  
 
 No evidence of liver disease;  
 Pregnancy;  
 Patients with pacemakers fitted.  
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The study was performed in accordance with the principles of the Declaration of Helsinki and its 
appendices and with local and national laws.  Project-specific ethical approval was 
successfully obtained on 3 December 2015 from the London City & East NRES Committee (REC 
reference 15/EE/0420). Full local Trust R&D approval was given on 3 March 2016 (Joint Research 
Compliance Office Reference N° 187875). This study was adopted as an NIHR CRN Portfolio 
study on 7 March 2016. Written informed consent was obtained from all patients. 
ElastPQ 
The Philips system EPIQ 7TM uses the C5- I Pure Waves transducer. Results can be displayed in 
m/s or in kPa. Fail-safe mode reduces false reading. The maximum penetration depth of ElastPQ 
was 8 cm and the region of interest (ROI) size measurement was depth dependent with 0.5 cm-1.5 
cm at the depth of 4 cm. The ROI measurement and quantitative value of liver stiffness was 
displayed over a B-mode ultrasound image.  
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Figure 4: Philips EPIQ 7TM    
 
Patients 
Each patient was placed supine with right arm raised behind his/her head and remained still during 
the procedure. Patients were fasted for up to 6 hours. 10 measurements were taken on the right lobe 
of the liver, 10 on the left lobe of the liver, 10 on the spleen and a median value calculated for every 
set of measurements. 
Breathing phase 
During a normal respiratory phase the participants were invited to hold their breath for a few 
seconds during the measurements so as to minimise breathing motion while avoiding deep 
inspiration or expiration. Elast PQ measurements were performed 10 times on the right lobe, 10 
times in the left lobe and 10 times in the spleen.  
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Liver location 
10 measurements were taken on the right lobe of the liver, and a median value calculated. On the 
right lobe of the liver the measurements were taken in approximately the same area where the 
biopsy was to be performed, an area where the liver tissue was at least 6 cm thick and free of large 
blood vessels. A measurement depth of 2 cm below the liver capsule was chosen to standardise the 
examination.  
 
Figure 5: Region of interest in shear-wave elastography measurement 
Probe position 
Scans of the right lobe of the liver were obtained through an intercostal approach and measurements 
were taken on the same segment as the liver biopsy. Elast PQ measurements were performed 10 
times on the right lobe, 10 times on the left lobe and 10 times on the spleen.  
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Measurement results 
The results are expressed in m/s and kPa. The median of 10 acquisitions was calculated. The 10 
measurements were taken in order to obtain the lowest IQR/M.  
Virtual Touch HD Tissue 
Acoustic Radiation Force Impulse imaging (Virtual Touch Tissue Quantification, Siemens 
ACUSON S2000, Siemens Medical Solutions, Mountain View, CA, USA) involves targeting an 
anatomic region to be interrogated for elastic properties with a region of interest (ROI) cursor while 
performing real-time B-mode imaging. Tissue at the ROI is mechanically excited using short-
duration acoustic pulses to generate localised tissue displacements in it. The displacements result in 
shear-wave propagation away from the region of excitation and are tracked using ultrasonic, 
correlation-based methods. The shear velocity increases with fibrosis severity and is estimated in 
the central window 5 mm axial by 4 mm wide, within a region of interest graphically displayed with 
a size of 1 cm axial by 6 mm width [132].  
Patients  
Each patient was placed supine with right arm raised behind his/her head and remained still during 
the procedure. Patients had fasted for up to 6 hours. 10 measurements were taken on the right lobe 




During a normal respiratory phase the participants were invited to hold their breath for a few 
seconds during the measurements. Virtual Touch measurements were performed 10 times on the 
right lobe of the liver, 10 on the left lobe and 10 on the spleen. 
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Probe position 
Scans on the right lobe of the liver were obtained through an intercostal approach and 
measurements were taken in the same segment as for the liver biopsy. Virtual Touch measurements 
were performed 10 times on the right lobe, 10 on the left lobe and 10 on the spleen.  
Liver location 
10 measurements were taken on the right lobe of the liver and a median value calculated. They were 
taken in approximately the same area as that where the biopsy was to be performed, an area where 
the liver tissue was at least 6 cm thick and free of large blood vessels. A measurement depth of 2 
cm below the liver capsule was chosen to standardise the examination.  
Measurement results 
Results are expressed in m/s then converted into kPa using the formula 3*(median in m/s)2. The 10 
measurements were taken in order to obtain the lowest IQR/M. 
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FibroscanTM 
TE provides only a 1D line and an M-mode image to localise the measurement site.   
Patients    
Each patient was placed supine with right arm raised behind his/her head and remained still during 
the procedure. With the probe over the liver region, readings were attempted until 10 valid 
measurements were obtained. 
Probe position 
All studies were started with an M+ probe, with an XL+ probe for rescue only when prompted by 
the automatic probe selection tool. In rare instances, where the machine’s recommendation 
fluctuated between M+ and XL+ probes, the study coordinator was instructed to choose the XL+ 
probe.  
Measurement results 
Only results with 10 valid shots and IQR/ median liver stiffness ratio <30% were included. 
CAP score  
CAP was computed only when the associated liver stiffness measurement was valid and using the 
same signals as the one used to measure liver stiffness. Therefore, both stiffness and CAP were 
obtained simultaneously and in the same volume of liver parenchyma (namely between 25 and 65 
mm). The final CAP value was the median of individual CAP values and was expressed in dB/m.  
Liver biopsy  
Liver biopsy was performed by the operator using an 18-gauge trucut needle (Bioprince Argon 
Medical devices INC) with ultrasound-guided approach. A minimum 20 mm long biopsy specimen 
was required.  
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Histological assessment 
A minimum 20 mm long biopsy specimen or the presence of at least 10 complete portal tracts was 
required.  
Core biopsy samples were placed in 10% formaldehyde solution and sent to the local 
Histopathology Department at St Mary’s Hospital.  
Two expert pathologists, who were blinded to the CAP results and liver stiffness measurement, 
analysed the liver biopsy (19).  
Liver biopsy specimens were formalin-fixed and paraffin-embedded. 4-mm thick sections were 
stained with haematoxylin-eosin-safran, Masson’s trichrome stain for collagen, Perl’s stain for iron 
and Gordon & Sweets stain for reticulin. Liver fibrosis stage and necroinflammatory activity grade 
were evaluated according to the Metavir or NAS score depending on the cause of disease. Steatosis 
was categorised by visual assessment steatosis and was defined according to the number of affected 
hepatocytes: S1 (5–33%, “mild”), S2 (33–66%, “moderate”), S3 (66%, “severe”). 
Blood samples 
Blood sample analysis was carried out at St Mary’s Hospital laboratory. 
Statistical Methods 
Statistical analysis was performed using SPSS, Version 24.0 (IBM Statistics). Spearman’s rank 
correlation coefficient was used to assess the correlation between TE and Elast PQ. Area under 
receiver operating characteristic (AUROC) curves were calculated for Elast PQ to identify 
discriminating cut-offs for various stages of liver fibrosis.  
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RESULTS 
This was a single-centre, cross-sectional study. 110 consecutive patients with liver disease who had 
been referred for a liver biopsy were scanned, immediately prior to their liver biopsy, using the 
Philips ultrasound system, Siemens Acuson S2000 ARFI ultrasound system and Echosens 
FibroscanTM. Liver biopsy was performed on the same day as the pSWE and TE measurements, as 
day-case procedures. Tests were performed in the morning after an overnight fast. The patients’ 
characteristics, epidemiological data and biochemical test results were recorded. 
Between March 2016 and December a total of 126 consecutive patients fulfilled the inclusion 
criteria. Among them, 9 were excluded because liver biopsy was considered unsuitable for staging. 
Finally, 110 patients were considered for subsequent analysis. No side-effect was observed. 
Patients’ characteristics are indicated in Table 1,2,3 . 
Liver stiffness measurements were not obtained in 2 patients by TE due to ascites. Reliable 
measurements by FibroscanTM were obtained by the M probe in 66 patients and by the XL probe in 
20 patients. The overall median values of liver stiffness for fibrosis stages and standard deviation of 
FibroscanTM, Elast PQ and Virtual Touch are illustrated in Table 3. 
A direct, strong correlation was observed between LS values assessed by TE elastography by Elast 
PQ and Virtual Touch (p < 0.0001) and Metavir score. 
The AUROCs (Area Under the Received Curves) were calculated considering the liver biopsy as 
the reference method.  
Areas under the Curve (AUC) are: TE 0.829; Elast PQTM 0.804; VTQ 0.696 for no or mild fibrosis 
(F0-F1 n=51) and TE 0.946; Elast PQTM 0.866; VTQ 0.852 for cirrhosis (F4, n= 15 positives).   
The mean optimal cut-off for no or mild fibrosis F0-F1 (n=51) are 8.15 kPa for TE (sensitivity 0.76 
and specificity 0.80); 7.15 KPa (sensitivity 0.72; specificity 0.80) for ElastPQTM and 8.2 KPa 
(sensitivity 0.70 and specificity 0.60) for VTQ. The mean optimal cut-off for cirrhosis F=4 (n=13) 
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are 15.1 kPa for TE (sensitivity was 0.92 and specificity 0.92); 10.80 KPa (sensitivity 0.84; 
specificity 0.87) for Elast PQTM and 11.82 KPa (sensitivity 0.84 and specificity 0.71) for VTQ.  
Mean value for Elast PQTM in the left lobe are higher to those obtained from the right lobe of the 
liver (Right 8.76 kPa; Left 9.95 kPa) but this is not statistically significant (p=0.105). 
The diagnostic accuracy (AUROC) of measures taken on the left lobe are: Elast PQTM 0.728; VTQ 
0.661 for no or mild fibrosis (F0-F1 n=52) and Elast PQTM 0.796; VTQ 0.773 for cirrhosis (F4, n= 
14 positives). 
The mean optimal cut-off for no or mild fibrosis F0-F1 (n=52) measured in the left lobe are: 8.3 
KPa (sensitivity 0.67; specificity 0.69) for ElastPQTM and 8.6 KPa (sensitivity 0.63 and specificity 
0.57) for VTQ. The mean optimal cut-off for cirrhosis F=4 (n=13) measured on the left lobe of the 
liver are: 10.18 KPa (sensitivity 0.71; specificity 0.71) for Elast PQTM and 11.82 KPa (sensitivity 
0.71 and specificity 0.76) for VTQ. 
Bland-Altman plot shows the agreement betweek Elast PQTM measurements taken on the right and 
left lobe of the liver. 
All the 3 techniques correlate with histological score of liver fibrosis (METAVIR score). 
Correlation with serum aminotransferase level shows a statistical significance for TE and Elast 
PQTM (r Elast PQTM 0.253; TE 0.273). Elast PQTM and Virtual Touch, but not TE, showed 
statistically significative correlation with lobular activity (Elast PQTM r 0.26; VTQ 0.26). There is 
no correlation in all the 3 techniques with histological presence of steatosis and body mass index 
(BMI). 
A linear regression analysis shows correlation between Elast PQTM measurements and interquartile 
range (IQR) (r2 0.50, p 0.002) and transaminases level (r2 0.064, p 0.002) and between VTQ 
measurements and IQR (r2 0.507, p 0.001).  
Positive correlation with both steatosis and ballooning on liver biopsy shows a statistical 
significance for CAP score (r Steatosis 0.558; Ballooning 0.473). CAP score doesn’t show 
statistically significative correlations with BMI and lobular activity (r 0.057; r 0.190 respectively). 
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Receiver operating characteristic (ROC) curves of steatosis and ballooning measured by CAP score 
show that CAP score is more accurate in the diagnosis of ballooning (AUROC 0.822) than steatosis 
(AUROC 0.782). 
Comparisons of spleen stiffness (SS) by Elast PQ in the group of patients with HIV and NCPH 
(n=11), in patients with HIV but no NCPH (n=11), in the subgroup of patients with cirrhosis and 
non portal hypertension (n= 15) and in patients with no fibrosis (F0, n 15), shows statistically 
higher values (p 0.01) in patient with NCPH compared to spleen stiffness in patients with HIV 
without NCPH and in patients with no fibrosis (F0). SS values are also higher but not statistically 
significative (p 0.060) compared to SS measurements in patients with cirrhosis.  
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DISCUSSION 
Liver biopsy is still considered the gold standard for the evaluation of chronic diffuse liver diseases. 
However, liver biopsy is an invasive procedure, and its complications occur in 0.6–5% of patients. 
In recent years, shear-wave-based ultrasound elastography has begun to play an increasingly 
important role in the assessment of liver stiffness. In this study, we correlated liver stiffness 
assessed by the Philips EPIQ 7TM Ultrasound System, Siemens Acuson (ARFI) ultrasound system 
and Echosens FibroscanTM (currently the best-validated technique), and compared the results of 
these three imaging techniques with histological results in 87 patients suffering from liver disease 
with different aetiologies. The results of our study showed that Elast PQ gave a good performance 
compared with TE and that the cut-off values for TE were 8.07 kPa for the diagnosis of significant 
fibrosis (fibrosis F1-F3) and 10.35 kPa for the diagnosis of cirrhosis (fibrosis F4).  The best liver 
stiffness cut-offs identified by the ROC curves able to maximise the accuracy of Elast PQ were 6.62 
kPa for the diagnosis of significant fibrosis (fibrosis F1-F3) and 8.09 kPa for the diagnosis of 
cirrhosis (fibrosis F4). These results are consistent with previous studies in the literature. 
The CAP score showed significant correlation with two histological components of NASH, 
steatosis and ballooning, but not for lobular activity.  This result could be related to an 
underestimation of steatosis in the histological results. Tissue sample lengths are usually 20 mm and 
could underestimate the percentage of steatosis that is often more present in zone 3, while the CAP 
score, having a more widely-explored volume, could give a better assessment of steatosis. 
Elevated spleen stiffness is observed in HIV patients with NCPH and can be quantified easily using 
shear wave elastography. Further evaluation for longitudinal monitoring of patients with portal 
hypertension should be considered.  
 
The multiple aetiologies of liver disease are a limitation of this study, but it reflects the different 
liver disease aetiologies that have undergone a liver biopsy as a standard of care. Considering the 
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fact that fewer patients undergo a liver biopsy nowadays, a sample size of 110 patients with liver 
biopsy is important to detect the reliability of non-invasive techniques.  
Further studies are needed in order to better understand non-invasive assessment of liver fibrosis 
and steatosis.    
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TABLES OF RESULTS 
 
 FREQUENCIES MEAN 
M 64  
F 46  
Age  47.98+-13.8 
Total 110  











Table 2 Patients’ profile. AIH: autoimmune hepatitis; NASH: non alcoholic steatohepatitis; HBV: chronic hepatitis B; HCV chronic 









Table 3: Histologica features according METAVIR score.  
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Mean 10.75 1.4 8.90 4.61 11.03 7.22 
Median 8.0 0.85 6.86 2.91 9.19 5.15 
SD 9.50 2.54 6.66 5.82 7.30 6.9 










Mean 9.95 6.93 10.74 7.31 
Median 8.27 3.98 8.78 4.86 
SD 7.98 10.04 6.53 5.82 










Mean 23.97 14.61 21.45 12.56 
Median 19.71 9.06 20.43 10.64 
SD 29.35 25.98 7.38 8.51 
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 Metavis ElastPQ VTQ Fibroscan ALT AST Platelet 

























































Table 7 Pearson Correlation 
 
 









 p 0.582 

















 p 0.584 
Table 8 Pearson Correlation 
 
 
 STEATOSIS BALLOONING LOBULAR ACTIVITY 


















Table 9 Pearson Correlation 
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Figure 2 Areas under the Curve (AUC): TE, Elast PQTM, VTQ for F4 
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Figure 4 Areas under the Curve (AUC) measured on the left lobe: Elast PQTM, VTQ for diagnosis of cirrhosis (F4) 
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Figure 6 Bland-Altman shows agreement between measurements taken on the right and left lobe of the liver by Virtual Touch 
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Figura 9 Distribution of spleen stiffness median values measured by Elast PQTM among patients with NCPH, cirrhotic patients and 
healthy controls. Spleen stiffness measurements in patients with HIV and non cirrhotic (NCPH); spleen stiffness measurement in 
patients with cirrhosis (F4); spleen stiffness measurements in patients with HIV and spleen stiffness measurements in patients 
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